"What" Series

What clinical indicator is BCVA?

28 April 2024
2 min read

BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity. It is the visual acuity measured when the patient is wearing the best corrective lenses (such as glasses or contact lenses) and reflects the best level of vision the patient can achieve with proper refractive correction.

The measurement of BCVA typically uses standardized vision charts, such as the ETDRS (Early Treatment Diabetic Retinopathy Study) chart, which provides a unified and quantified method for assessing visual acuity. The ETDRS chart uses the LogMAR (logarithm of the minimum angle of resolution) scoring system, allowing scoring letter by letter, thus providing higher accuracy for visual acuity measurement.

In clinical research, BCVA is an important indicator for evaluating the effectiveness of ophthalmic treatment methods and can serve as a primary endpoint to assess the impact of new treatments on vision improvement. Furthermore, the standardized measurement and data collection of BCVA are crucial for the success of clinical trials. Standardized processes with certified and centralized data review help accurately quantify changes in visual acuity.

Improvement in BCVA is generally considered a sign of successful treatment, especially in treating retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME). In the late stages of certain eye diseases, traditional efficacy endpoints may not be applicable, and new clinical endpoints may need to be developed to measure treatment effects, such as multi-luminance mobility testing (MLMT) or full-field stimulus testing.

In summary, BCVA is an important clinical indicator used to evaluate the visual acuity of ophthalmic patients and the effectiveness of treatments. It is of great significance for guiding clinical treatment decisions and new drug development.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial of ARO-CFB for Kidney Diseases Linked to Complement System Dysfunctions
Latest Hotspot
3 min read
Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial of ARO-CFB for Kidney Diseases Linked to Complement System Dysfunctions
26 April 2024
Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 26
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 26
26 April 2024
April 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
FDA Approves Novartis's Lutathera® as First Specific Treatment for Young Patients with Gastroenteropancreatic Neuroendocrine Tumors
Latest Hotspot
3 min read
FDA Approves Novartis's Lutathera® as First Specific Treatment for Young Patients with Gastroenteropancreatic Neuroendocrine Tumors
26 April 2024
The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.
Read →
What is the Therapeutic Index (TI)?
"What" Series
2 min read
What is the Therapeutic Index (TI)?
26 April 2024
The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.